Journal articles: 'Colloidal drug delivery systems'

1

Duncan-Hewitt, Wendy C. "Colloidal drug delivery systems." Colloids and Surfaces B: Biointerfaces 5, no. 1-2 (September 1995): 89–90. http://dx.doi.org/10.1016/0927-7765(95)90010-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Brannon-Peppas, Lisa. "Colloidal drug delivery systems." Journal of Controlled Release 37, no. 3 (December 1995): 307–8. http://dx.doi.org/10.1016/0168-3659(95)90003-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Peracchia, Maria Teresa. "Colloidal drug delivery systems." Journal of Controlled Release 35, no. 2-3 (August 1995): 181–82. http://dx.doi.org/10.1016/0168-3659(95)90034-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Beg, Sarwar, Abdus Samad, Iram Nazish, Ruksar Sultana, Mahfoozur Rahman, Md Zaki Ahmad, and Md Akbar. "Colloidal Drug Delivery Systems in Vaccine Delivery." Current Drug Targets 14, no. 1 (December 1, 2012): 123–37. http://dx.doi.org/10.2174/1389450111314010013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Beg, Sarwar, Abdus Samad, Iram Nazish, Ruksar Sultana, Mahfoozur Rahman, Md Zaki Ahmad, and Md Akbar. "Colloidal Drug Delivery Systems in Vaccine Delivery." Current Drug Targets 14, no. 1 (January 1, 2013): 123–37. http://dx.doi.org/10.2174/138945013804806523.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Singh, Sukhbir, Neelam Sharma, Tapan Behl, Bidhan Chandra Sarkar, Hasi Rani Saha, Kanika Garg, Supriya Kamari Singh, et al. "Promising Strategies of Colloidal Drug Delivery-Based Approaches in Psoriasis Management." Pharmaceutics 13, no. 11 (November 22, 2021): 1978. http://dx.doi.org/10.3390/pharmaceutics13111978.

Full text

Abstract:

Psoriasis is a chronic inflammatory autoimmune disorder that moderately affects social and interpersonal relationships. Conventional treatments for psoriasis have certain problems, such as poor drug penetration through the skin, hyper-pigmentation, and a burning sensation on normal and diseased skin. Colloidal drug delivery systems overcome the pitfalls of conventional approaches for psoriasis therapeutics and have improved patient safety parameters, compliance, and superior effectiveness. They also entail reduced toxicity. This comprehensive review’s topics include the pathogenesis of psoriasis, causes and types of psoriasis, conventional treatment alternatives for psoriasis, the need for colloidal drug delivery systems, and recent studies in colloidal drug delivery systems for the treatment of psoriasis. This review briefly describes colloidal drug delivery approaches, such as emulsion systems—i.e., multiple emulsion, microemulsion, and nano-emulsion; vesicular systems—i.e., liposomes, ethosomes, noisomes, and transferosomes; and particulate systems—i.e., solid lipid nanoparticles, solid lipid microparticles, nano-structured lipid carriers, dendrimers, nanocrystals, polymeric nanoparticles, and gold nanoparticles. The review was compiled through an extensive search of the literature through the PubMed, Google Scholar, and ScienceDirect databases. A survey of literature revealed seven formulations based upon emulsion systems, six vesicular drug delivery systems, and fourteen particulate systems reported for antipsoriatic drugs. Based on the literature studies of colloidal approaches for psoriasis management carried out in recent years, it has been concluded that colloidal pharmaceutical formulations could be investigated broadly and have a broad scope for effective management of many skin disorders in the coming decades.

APA, Harvard, Vancouver, ISO, and other styles

7

Mishra, Vijay, Kuldeep Bansal, Asit Verma, Nishika Yadav, Sourav Thakur, Kalvatala Sudhakar, and Jessica Rosenholm. "Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems." Pharmaceutics 10, no. 4 (October 18, 2018): 191. http://dx.doi.org/10.3390/pharmaceutics10040191.

Full text

Abstract:

Solid lipid nanoparticles (SLNs) are nanocarriers developed as substitute colloidal drug delivery systems parallel to liposomes, lipid emulsions, polymeric nanoparticles, and so forth. Owing to their unique size dependent properties and ability to incorporate drugs, SLNs present an opportunity to build up new therapeutic prototypes for drug delivery and targeting. SLNs hold great potential for attaining the goal of targeted and controlled drug delivery, which currently draws the interest of researchers worldwide. The present review sheds light on different aspects of SLNs including fabrication and characterization techniques, formulation variables, routes of administration, surface modifications, toxicity, and biomedical applications.

APA, Harvard, Vancouver, ISO, and other styles

8

Naeem, Sumaira, Geetha Viswanathan, and Misni Bin Misran. "Liposomes as colloidal nanovehicles: on the road to success in intravenous drug delivery." Reviews in Chemical Engineering 34, no. 3 (April 25, 2018): 365–83. http://dx.doi.org/10.1515/revce-2016-0018.

Full text

Abstract:

AbstractThe advancement of research in colloidal systems has led to the increased application of this technology in more effective and targeted drug delivery. Nanotechnology enables control over functionality parameters and allows innovations in biodegradable, biocompatible, and stimuli-responsive delivery systems. The first closed bilayer phospholipid system, the liposome system, has been making steady progress over five decades of extensive research and has been efficient in achieving many desirable parameters such as remote drug loading, size-controlling measures, longer circulation half-lives, and triggered release. Liposome-mediated drug delivery has been successful in overcoming obstacles to cellular and tissue uptake of drugs with improved biodistributionin vitroandin vivo. These colloidal nanovehicles have moved on from a mere concept to clinical applications in various drug delivery systems for antifungal, antibiotic, and anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

9

Swamy, P. V., Ch Sucharitha, and G. Surendra Babu. "A REVIEW ON PRONIOSOMES: A PRO-COLLOIDAL PARTICULATE DRUG CARRIER." International Journal of Research in Ayurveda and Pharmacy 11, no. 6 (December 30, 2020): 119–30. http://dx.doi.org/10.7897/2277-4343.1106198.

Full text

Abstract:

Colloidal particulate carrier systems are the systems which carry particulates in a nanometre size. These systems are substantially effective for transportation and distribution of variety of loaded drugs to desired site and increase efficacy and decrease toxicity, to provide therapeutic activity in a controlled manner for a prolonged period of time. One such new emerging colloidal systems is proniosomes which has capacity to improve the bioavailability and also permeation of drugs across the stratum corneum to provide a controlled release action and reduce toxic effects associated with drugs. These are the dry formulations of water-soluble non-ionic surfactant coated carrier systems which immediately on hydration form niosomes. They have the capacity to overcome the various problems associated with niosomes and liposomes, like instability, transportation, distribution, storage and dosing. They offer versatile drug delivery concept for both hydrophilic and hydrophobic drugs. They have the capacity to deliver drugs effectively through different routes at specific site to achieve controlled release action. This review concentrates on preparation, characterization, components, structure, types, evaluation parameters, proniosomes in drug delivery and targeting, toxicities associated with proniosomes, proniosomes versus niosomes, clinical applications, mechanism of vesicle formation in proniosomes and future trends associated with it. Also, drug delivery via different routes, such as oral, parenteral, topical and transdermal, ocular, vaginal, mucosal, pulmonary and intranasal were discussed.

APA, Harvard, Vancouver, ISO, and other styles

10

Krishna Sailaja, Abbaraju, and Ganparaju Vaishnavi. "Overall Review On Permeation Enhancers in Drug Delivery Systems." Archives of Medical Case Reports and Case Study 4, no. 3 (July 21, 2021): 01–04. http://dx.doi.org/10.31579/2692-9392/051.

Full text

Abstract:

60%-70% Several drugs can be administered orally as liquids, capsules, tablets, or chewable tablets because the oral route is the most convenient, safest and less expensive. The important challenge in the oral drug delivery is the growth of novel approaches to approve absorption of poorly permeable drugs across the intestinal permeability. The Biopharmaceutics Classification System (BCS) categorized based on their solubility and permeability. The BCS Class III, Class IV with low permeability across the biological membranes with low bioavailability. While these drugs are pharmacologically effective, poor absorption due to low permeability becomes the rate-limiting step to improve oral bioavailability. Various approaches for improving the permeability include physical, chemical, colloidal carriers and other methods such as prodrugs, permeation enhancers, ion-pairing, nanoencapsulation and combination/hybridization of one or more traditional approaches to improve drug permeability for better absorption. Among many advantages over other routes of administration 3 crucial ones are avoiding metabolism in liver, minimal negative effects and increased bioavailability.This article discusses the commonly various strategiesand various approaches for improving the permeability of BCS Class III and Class IVdrugs to enhance bioavailability.

APA, Harvard, Vancouver, ISO, and other styles

11

Madkhali, Osama A. "Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems." Molecules 27, no. 5 (February 24, 2022): 1543. http://dx.doi.org/10.3390/molecules27051543.

Full text

Abstract:

Combating multiple drug resistance necessitates the delivery of drug molecules at the cellular level. Novel drug delivery formulations have made it possible to improve the therapeutic effects of drugs and have opened up new possibilities for research. Solid lipid nanoparticles (SLNs), a class of colloidal drug carriers made of lipids, have emerged as potentially effective drug delivery systems. The use of SLNs is associated with numerous advantages such as low toxicity, high bioavailability of drugs, versatility in the incorporation of hydrophilic and lipophilic drugs, and the potential for production of large quantities of the carrier systems. The SLNs and nanostructured lipid carriers (NLCs) are the two most frequently used types of nanoparticles. These types of nanoparticles can be adjusted to deliver medications in specific dosages to specific tissues, while minimizing leakage and binding to non-target tissues.

APA, Harvard, Vancouver, ISO, and other styles

12

Garnett, M. C., S. Stolnik, S. E. Dunn, I. Armstrong, Wu Lin, E. Schacht, P. Ferutti, et al. "Application of Novel Biomaterials in Colloidal Drug Delivery Systems." MRS Bulletin 24, no. 5 (May 1999): 49–56. http://dx.doi.org/10.1557/s0883769400052325.

Full text

Abstract:

The development of biomaterials to treat, repair, or reconstruct the human body is an increasingly important component of materials research. Collaboration between materials researchers and their industrial and clinical partners is essential for the development of this complex field. To demonstrate the importance of these interactions, two articles in this issue focus on advances in biomaterials relating to the use of colloidal systems for transport, drug delivery, and other medical applications. These articles were coordinated by Dominique Muster (Université Louis Pasteur, Strasbourg) and Franz Burny (Hôpital Erasme, Brussels). The following is the second of these two articles.There are two important objectives in drug delivery research. The first is to maximize the effectiveness of drugs by increasing the amount of drug reaching the target tissue while sparing other tissues the deleterious effects of the drug. The second is to control the release of a drug, so that the period of optimal drug concentration in the target tissue is maximized. A numbe r of different Systems have been investigated to achieve these objectives, including soluble polymeric delivery Systems and a range of colloidal drug delivery forms such as liposomes, emulsions, micelles, microcapsules, microparticles, and nanoparticles. This article focuses on polymeric materials for the production of micro- or nanoparticle Systems for dru g delivery by injection, and their characterization and Performance in vivo.Colloidal particles have a number of advantages as drug delivery Systems; they are easy to prepare, have the potential for high drug loading, and release of the drug can be controlled. However, without surface modification, colloidal particles are difficult to target because they are directed largely to the liver and spieen after intravenous injection. The reasons for this can be found in the context of the body's defenses. In order to protect against disease, the body has a complex System to ensure that invading microorganisms are identified and neutralized at the earliest possible opportunity. Most parasitic or invading organisms which pose a threat are particulate in form, and thus any colloidal drug delivery System will have to evade detection by these mechanisms in order to reach its target.

APA, Harvard, Vancouver, ISO, and other styles

13

Swamy, N. G. N., and Z. Abbas. "SOLID LIPID NANOPARTICLES: EMERGING COLLOIDAL CARRIERS AS OCULAR DRUG DELIVERY SYSTEMS." INDIAN DRUGS 50, no. 04 (April 25, 2013): 5–25. http://dx.doi.org/10.53879/id.50.04.p0005.

Full text

Abstract:

Numerous attempts have been made to improve the bioavailability from ocular drug delivery systems and to prolong the residence time of drugs applied topically onto the eye. Conventional ocular drug delivery systems such as eye drops and ointments are inefficient, whereas, systemic administration requires high doses which may result in significant toxicity. Therefore, a need arises to develop novel drug delivery carrier systems capable of increasing ocular bioavailability and decreasing both local and systemic cytotoxicity. Nanotechnology is expected to revolutionize ocular drug delivery. Solid lipid nanoparticles (SLNs) introduced in 1991 represent an alternative carrier system to traditional colloidal carriers, such as emulsions, liposomes and polymeric micro- and nanoparticles. SLNs do not show biotoxicity as they are prepared from physiological lipids and are ideal ocular drug delivery systems as they can enhance the corneal absorption of drugs and improve the ocular bioavailability of both hydrophilic and lipophilic drugs. SLNs have another advantage of allowing autoclave sterilization, an indispensible step in the formulation of ocular preparations. In this review a special attention has been given to the nature of lipids and surfactants commonly used for SLNs production. This article also reviews in detail the various fabrication methods, characterization, sterilization, and stabilization techniques for SLNs. In-vitro and in-vivo methods to study the drug release profile from SLNs have also been mentioned. A summary of previous studies involving the use of SLNs in ocular drug delivery is provided, along with a critical evaluation of SLNs as a potential colloidal ocular drug delivery system.

APA, Harvard, Vancouver, ISO, and other styles

14

Swamy, N. G. N., and Z. Abbas. "SOLID LIPID NANOPARTICLES: EMERGING COLLOIDAL CARRIERS AS OCULAR DRUG DELIVERY SYSTEMS." INDIAN DRUGS 50, no. 04 (April 25, 2013): 5–25. http://dx.doi.org/10.53879/id.50.04.p0005.

Full text

Abstract:

Numerous attempts have been made to improve the bioavailability from ocular drug delivery systems and to prolong the residence time of drugs applied topically onto the eye. Conventional ocular drug delivery systems such as eye drops and ointments are inefficient, whereas, systemic administration requires high doses which may result in significant toxicity. Therefore, a need arises to develop novel drug delivery carrier systems capable of increasing ocular bioavailability and decreasing both local and systemic cytotoxicity. Nanotechnology is expected to revolutionize ocular drug delivery. Solid lipid nanoparticles (SLNs) introduced in 1991 represent an alternative carrier system to traditional colloidal carriers, such as emulsions, liposomes and polymeric micro- and nanoparticles. SLNs do not show biotoxicity as they are prepared from physiological lipids and are ideal ocular drug delivery systems as they can enhance the corneal absorption of drugs and improve the ocular bioavailability of both hydrophilic and lipophilic drugs. SLNs have another advantage of allowing autoclave sterilization, an indispensible step in the formulation of ocular preparations. In this review a special attention has been given to the nature of lipids and surfactants commonly used for SLNs production. This article also reviews in detail the various fabrication methods, characterization, sterilization, and stabilization techniques for SLNs. In-vitro and in-vivo methods to study the drug release profile from SLNs have also been mentioned. A summary of previous studies involving the use of SLNs in ocular drug delivery is provided, along with a critical evaluation of SLNs as a potential colloidal ocular drug delivery system.

APA, Harvard, Vancouver, ISO, and other styles

15

Jain, Shikha, Vikas Jain, and S. C. Mahajan. "Lipid Based Vesicular Drug Delivery Systems." Advances in Pharmaceutics 2014 (September 2, 2014): 1–12. http://dx.doi.org/10.1155/2014/574673.

Full text

Abstract:

Vesicular drug delivery system can be defined as highly ordered assemblies consisting of one or more concentric bilayers formed as a result of self-assembling of amphiphilic building blocks in presence of water. Vesicular drug delivery systems are particularly important for targeted delivery of drugs because of their ability to localize the activity of drug at the site or organ of action thereby lowering its concentration at the other sites in body. Vesicular drug delivery system sustains drug action at a predetermined rate, relatively constant (zero order kinetics), efficient drug level in the body, and simultaneously minimizes the undesirable side effects. It can also localize drug action in the diseased tissue or organ by targeted drug delivery using carriers or chemical derivatization. Different types of pharmaceutical carriers such as polymeric micelles, particulate systems, and macro- and micromolecules are presented in the form of novel drug delivery system for targeted delivery of drugs. Particulate type carrier also known as colloidal carrier system, includes lipid particles, micro- and nanoparticles, micro- and nanospheres, polymeric micelles and vesicular systems like liposomes, sphingosomes, niosomes, transfersomes, aquasomes, ufasomes, and so forth.

APA, Harvard, Vancouver, ISO, and other styles

16

Riess, Jean G., and Marie Pierre Krafft. "Fluorocarbons and Fluorosurfactants for In Vivo Oxygen Transport (Blood Substitutes), Imaging, and Drug Delivery." MRS Bulletin 24, no. 5 (May 1999): 42–48. http://dx.doi.org/10.1557/s0883769400052313.

Full text

Abstract:

The development of biomaterials to treat, repair, or reconstruct the human body is an increasingly important component of materials research. Collaboration between materials researchers and their industrial and clinical partners is essential for the development of this complex field. To demonstrate the importance of these interactions, two articles in this issue focus on advances in biomaterials relating to the use of colloidal systems for transport, drug delivery, and other medical applications. These articles were coordinated by Dominique Muster (Université Louis Pasteur, Strasbourg) and Franz Burny (Hôpital Erasme, Brussels). The following is the first of these two articles.A large variety of colloidal Systems involving highly fluorinated components have been prepared and investigated in recent years. These fluorinated Systems comprise diverse ty pes of emulsions (e.g., direct, reverse, and multiple emulsions; microemulsions; gel emulsions; waterless emulsions) with a fluorocarbon phase (and often a fluorinated Surfactant), and a ränge of self-assemblies (vesicles, tubules, helices, ribbons, etc.) made from fluorinated amphiphiles. Fluorinated Langmuir films and fluorinated black lipid membranes (BLMs) also have been investigated.Research in this area was driven by the potential applications of such materials in medicine and biology. Fluorocarbon-based products are being developed as injectable oxygen carriers (“blood Substitutes”), media for liquid Ventilation, drug delivery Systems, and contrast agents for ultrasound imaging. One such agent has recently been approved for use in Europe and the United States. Several more products are in an advanced stage of clinical evaluation, and others are in various stages of preclinical development. From a more fundamental Standpoint, these materials are being investigated for assessing and understanding the impact that fluorinated components have on the formation, stability, structure, and properties of colloida l Systems in comparison with their hydrocarbon counterparts. The attention given to fluorinated colloids prompted the synthesis of numerous new families of fluorinated amphiphiles, which were to become components of such colloids.

APA, Harvard, Vancouver, ISO, and other styles

17

Tejashri, Gursalkar, Bajaj Amrita, and Jain Darshana. "Cyclodextrin based nanosponges for pharmaceutical use: A review." Acta Pharmaceutica 63, no. 3 (September 1, 2013): 335–58. http://dx.doi.org/10.2478/acph-2013-0021.

Full text

Abstract:

Abstract Nanosponges are a novel class of hyper-crosslinked polymer based colloidal structures consisting of solid nanoparticles with colloidal sizes and nanosized cavities. These nano-sized colloidal carriers have been recently developed and proposed for drug delivery, since their use can solubilize poorly water-soluble drugs and provide prolonged release as well as improve a drug’s bioavailability by modifying the pharmacokinetic parameters of actives. Development of nanosponges as drug delivery systems, with special reference to cyclodextrin based nanosponges, is presented in this article. In the current review, attempts have been made to illustrate the features of cyclodextrin based nanosponges and their applications in pharmaceutical formulations. Special emphasis has been placed on discussing the methods of preparation, characterization techniques and applications of these novel drug delivery carriers for therapeutic purposes. Nanosponges can be referred to as solid porous particles having a capacity to load drugs and other actives into their nanocavity; they can be formulated as oral, parenteral, topical or inhalation dosage forms. Nanosponges offer high drug loading compared to other nanocarriers and are thus suitable for solving issues related to stability, solubility and delayed release of actives. Controlled release of the loaded actives and solubility enhancement of poorly water-soluble drugs are major advantages of nanosponge drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

18

Upadhyay, Ravi Kant. "Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier." BioMed Research International 2014 (2014): 1–37. http://dx.doi.org/10.1155/2014/869269.

Full text

Abstract:

Present review highlights various drug delivery systems used for delivery of pharmaceutical agents mainly antibiotics, antineoplastic agents, neuropeptides, and other therapeutic substances through the endothelial capillaries (BBB) for CNS therapeutics. In addition, the use of ultrasound in delivery of therapeutic agents/biomolecules such as proline rich peptides, prodrugs, radiopharmaceuticals, proteins, immunoglobulins, and chimeric peptides to the target sites in deep tissue locations inside tumor sites of brain has been explained. In addition, therapeutic applications of various types of nanoparticles such as chitosan based nanomers, dendrimers, carbon nanotubes, niosomes, beta cyclodextrin carriers, cholesterol mediated cationic solid lipid nanoparticles, colloidal drug carriers, liposomes, and micelles have been discussed with their recent advancements. Emphasis has been given on the need of physiological and therapeutic optimization of existing drug delivery methods and their carriers to deliver therapeutic amount of drug into the brain for treatment of various neurological diseases and disorders. Further, strong recommendations are being made to develop nanosized drug carriers/vehicles and noninvasive therapeutic alternatives of conventional methods for better therapeutics of CNS related diseases. Hence, there is an urgent need to design nontoxic biocompatible drugs and develop noninvasive delivery methods to check posttreatment clinical fatalities in neuropatients which occur due to existing highly toxic invasive drugs and treatment methods.

APA, Harvard, Vancouver, ISO, and other styles

19

Koroleva, Marina Y., Dmitry Bidanov, and Evgeny Yurtov. "Nano- and microcapsules as drug-delivery systems." Resource-Efficient Technologies, no. 4 (December 2, 2016): 233–39. http://dx.doi.org/10.18799/24056529/2016/4/68.

Full text

Abstract:

Preparation of nano- and micrometer-size capsules with lipid core might have several biomedical applications for delivery of lipophilic drugs. Successful usage of these nano- and microcarriers depends on their colloidal stability. Emulsion based carriers for drug delivery: nanoemulsions, colloidosomes, and solid lipid particles have been investigated in thiswork. Diameters of oil droplets in nanoemulsions are equal to 15 and 20 nm, howeverthey are not stable to phase separation. In spite of large droplet diameters (several tens of micrometer), colloidosomes stabilized by heteroaggregates of oppositely charged SiO2 nanoparticles are stable toward creaming. Paraffin emulsions stabilized by Carbopol 940 have particles 190 nm in size and are also stable to creaming during several months. Encapsulation of lipophilic drugs tocopherol, hydrocortisone, nimesulide or curcumin does not cause changing diameters of nanoemulsion based nanocapsules. Incorporation of these drugs in paraffin particles leads to decreased or increased particle sizes, but in all specimens the sizes are equal or less than 700 nm and such particles can be used as microcapsules for lipophilic drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

20

Basak, Ankita, Soumyadip Ghosh, Debgopal Ganguly, Soukat Garain, Riya Ghosh, Ananta Choudhury, Himangshu Deka, and Jahnabi Sarmah. "Current trends and future perspectives of natural polymer loaded nanoparticle based drug delivery system for the management of inflammatory bowel disease." Journal of Applied Pharmaceutical Research 11, no. 4 (October 31, 2023): 1–9. http://dx.doi.org/10.18231/j.joapr.2023.11.4.1.9.

Full text

Abstract:

Targeting the drug delivery system is very tough nowadays due to premature drug release at the upper GIT tract and altered pH conditions. Colon-specific drug delivery systems can overcome that problem using different polymer combinations. A nanoparticulate drug delivery system is the prominent dosage form that impacts the bioavailability and requires a low dose to excrete the therapeutic efficacy. All nanoscience and nanotechnology are applications of Nanometrology, the science of measurements at the nanoscale. NPDDSs were primarily developed to combine the colloidal stability of solid particle suspensions in biological fluids and the solubilizing properties of liquids. An ideal drug-delivery system possesses two elements: the ability to target and control the drug release. Colloidal drug carriers offer a number of potential advantages as delivery systems, such as better bioavailability for poorly soluble drugs. Researchers have created various sophisticated and multifunctional nanocarrier systems that can transport pharmaceuticals in a targeted, sustained, and regulated manner to provide therapeutic medications that are safer and more effective, particularly to ulcerative colitis. These innovative technologies are improving the pharmacokinetic profile of pharmaceuticals, increasing their systemic circulation, and decreasing the frequency of pharmacological side effects. The review focuses on the current trend and future perspectives of natural polymer-based-loaded nanoparticle-based drug delivery systems for the management of inflammatory bowel disease.

APA, Harvard, Vancouver, ISO, and other styles

21

Escareno, Noe, Antonio Topete, Pablo Taboada, and Adrian Daneri-Navarro. "Rational Surface Engineering of Colloidal Drug Delivery Systems for Biological Applications." Current Topics in Medicinal Chemistry 18, no. 14 (October 10, 2018): 1224–41. http://dx.doi.org/10.2174/1568026618666180810145234.

Full text

Abstract:

The use of colloidal particles as drug delivery carriers holds a great promise in terms of improvement of traditional treatment and diagnosis of human diseases. Nano- and microsized particles of a different composition including organic and inorganic materials can be fabricated with a great control over size, shape and surface properties. Nevertheless, only some few formulations have surpassed the benchtop and reached the bedside. The principal obstacle of colloidal drug delivery systems is their poor accumulation in target tissues, organs and cells, mainly by efficient sequestration and elimination by the mononuclear phagocytic system. Recent evidence suggests that, besides size, the surface character of colloidal systems is the most determinant design parameter that may ultimately guarantee successful biological performance. To approach these issues, materials designers and engineers can make use of multiple strategies and tools to finely modulate the particles’ surface towards highly efficient and biocompatible materials. In this article, we provide an overview of the most relevant colloidal drug delivery systems, a summary of the available literature regarding the effects of surface charge, hydrophobicity and softness on biological response, and finally, we review the key points of surface modification strategies with organic, inorganic and biological materials.

APA, Harvard, Vancouver, ISO, and other styles

22

Garg, Tarun, Goutam Rath, and Amit Kumar Goyal. "Colloidal Drug Delivery Systems: Current Status and Future Directions." Critical Reviews in Therapeutic Drug Carrier Systems 32, no. 2 (2015): 89–147. http://dx.doi.org/10.1615/critrevtherdrugcarriersyst.2015010159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Mondon, Karine, Robert Gurny, and Michael Möller. "Colloidal Drug Delivery Systems – Recent Advances With Polymeric Micelles." CHIMIA International Journal for Chemistry 62, no. 10 (October 29, 2008): 832–40. http://dx.doi.org/10.2533/chimia.2008.832.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Beija, Mariana, Robert Salvayre, Nancy Lauth-de Viguerie, and Jean-Daniel Marty. "Colloidal systems for drug delivery: from design to therapy." Trends in Biotechnology 30, no. 9 (September 2012): 485–96. http://dx.doi.org/10.1016/j.tibtech.2012.04.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Vonarbourg, Arnaud, Catherine Passirani, Patrick Saulnier, and Jean-Pierre Benoit. "Parameters influencing the stealthiness of colloidal drug delivery systems." Biomaterials 27, no. 24 (August 2006): 4356–73. http://dx.doi.org/10.1016/j.biomaterials.2006.03.039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Boyd, Ben J. "Past and future evolution in colloidal drug delivery systems." Expert Opinion on Drug Delivery 5, no. 1 (December 21, 2007): 69–85. http://dx.doi.org/10.1517/17425247.5.1.69.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Riabtseva, Anna, Nataliya Mitina, Nataliya Boiko, Sergiy Garasevich, Igor Yanchuk, Rostyslav Stoika, Oleksandr Slobodyanyuk, and Alexander Zaichenko. "Structural and Colloidal-Chemical Characteristics of Nanosized Drug Delivery Systems Based on Pegylated Comb-Like Carriers." Chemistry & Chemical Technology 6, no. 3 (September 20, 2012): 291–95. http://dx.doi.org/10.23939/chcht06.03.291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Sugumaran, Abimanyu, and Vishali Mathialagan. "Colloidal Nanocarriers as Versatile Targeted Delivery Systems for Cervical Cancer." Current Pharmaceutical Design 26, no. 40 (November 27, 2020): 5174–87. http://dx.doi.org/10.2174/1381612826666200625110950.

Full text

Abstract:

Background: The second most common malignant cancer of the uterus is cervical cancer, which is present worldwide, has a rising death rate and is predominant in developing countries. Different classes of anticancer agents are used to treat cervical carcinoma. The use of these agents results in severe untoward side-effects, toxicity, and multidrug resistance (MDR) with higher chances of recurrence and spread beyond the pelvic region. Moreover, the resulting clinical outcome remains very poor even after surgical procedures and treatment with conventional chemotherapy. Because of the nonspecificity of their use, the agents wipe out both cancerous and normal tissues. Colloidal nano dispersions have now been focusing on site-specific delivery for cervical cancer, and there has been much advancement. Methods: This review aims to highlight the problems in the current treatment of cervical cancer and explore the potential of colloidal nanocarriers for selective delivery of anticancer drugs using available literature. Results: In this study, we surveyed the role and potential of different colloidal nanocarriers in cervical cancer, such as nanoemulsion, nanodispersions, polymeric nanoparticles, and metallic nanoparticles and photothermal and photodynamic therapy. We found significant advancement in colloidal nanocarrier-based cervical cancer treatment. Conclusion: Cervical cancer-targeted treatment with colloidal nanocarriers would hopefully result in minimal toxic side effects, reduced dosage frequency, and lower MDR incidence and enhance the patient survival rates. The future direction of the study should be focused more on the regulatory barrier of nanocarriers based on clinical outcomes for cervical cancer targeting with cost-effective analysis.

APA, Harvard, Vancouver, ISO, and other styles

29

Patel, A. R., and K. P. Velikov. "Colloidal delivery systems in foods: A general comparison with oral drug delivery." LWT - Food Science and Technology 44, no. 9 (November 2011): 1958–64. http://dx.doi.org/10.1016/j.lwt.2011.04.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Shivanshi Saini, Rajeev Tomar, Neha Saini, Devender Nath, Ramesh Kumar, Mohd. Haneef, Divyansh Kateja, Govind Upadhayay, and Yasir Ansari. "A critical review on formulation and evaluation of colon targeted drug delivery systems." World Journal of Advanced Research and Reviews 17, no. 2 (February 28, 2023): 544–50. http://dx.doi.org/10.30574/wjarr.2023.17.2.0305.

Full text

Abstract:

A multidisciplinary scientific field that is fast growing is nanotechnology, often known as molecularly generated systems and technologies. Nanotechnology is a rapidly expanding field of applied science and engineering. It relies upon the concept of nano-scale manipulation of matter, meaning the ability to handle materials on a microscopic scale. Nanoparticles can be used to deliver a variety of substances, including conventional drugs, recombinant proteins, vaccines, and more recently nucleotides. Nanoparticles and other colloidal drug delivery techniques change the kinetics, body distribution, and drug release of a related drug. The treatment of negative effects and the distribution of therapy that targets certain tissues or cells are additional effects. As a result, nanoparticles in the pharmaceutical and biotechnology industries boost the therapeutic index and provide solutions to impending delivery problems for new classes of so-called biotech medicines such recombinant proteins and oligonucleotides.

APA, Harvard, Vancouver, ISO, and other styles

31

Marchenko, Irina V., and Daria B. Trushina. "Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems." Pharmaceutics 15, no. 12 (December 3, 2023): 2724. http://dx.doi.org/10.3390/pharmaceutics15122724.

Full text

Abstract:

Treatment of bladder cancer remains a critical unmet need and requires advanced approaches, particularly the development of local drug delivery systems. The physiology of the urinary bladder causes the main difficulties in the local treatment of bladder cancer: regular voiding prevents the maintenance of optimal concentration of the instilled drugs, while poor permeability of the urothelium limits the penetration of the drugs into the bladder wall. Therefore, great research efforts have been spent to overcome these hurdles, thereby improving the efficacy of available therapies. The explosive development of nanotechnology, polymer science, and related fields has contributed to the emergence of a number of nanostructured vehicles (nano- and micro-scale) applicable for intravesical drug delivery. Moreover, the engineering approach has facilitated the design of several macro-sized depot systems (centimeter scale) capable of remaining in the bladder for weeks and months. In this article, the main rationales and strategies for improved intravesical delivery are reviewed. Here, we focused on analysis of colloidal nano- and micro-sized drug carriers and indwelling macro-scale devices, which were evaluated for applicability in local therapy for bladder cancer in vivo.

APA, Harvard, Vancouver, ISO, and other styles

32

Alkufi, Hussein, Ahmed Salman, and Salam Taher. "Principles and Advantages of New Drug Delivery Technologie." Journal of Complementary Medicine Research 14, no. 3 (2023): 6. http://dx.doi.org/10.5455/jcmr.2023.14.03.02.

Full text

Abstract:

Advanced drug delivery systems offer undeniable benefits for drug delivery. In the past three decades, new methods have been proposed to develop a novel carriers for drug delivery. Nowadays, the major goal is to maximize therapeutic benefit while minimizing side effects. Drug delivery technique is clearly shifting from the micro to nanoscale. Nano-drug delivery systems (NDDSs) are the most promising approach utilized to improve the accuracy of drug delivery and the efficacy of drugs.In this narrative review article, we evaluate how delivery challenges associated with commercial marketed products and discuss newer DDS is being carried out to overcome these challenges .Different colloidal carrier systems such as carbon nanotube ,liposome , were being studied and extensively investigated.

APA, Harvard, Vancouver, ISO, and other styles

33

Bunjes, Heike. "Structural properties of solid lipid based colloidal drug delivery systems." Current Opinion in Colloid & Interface Science 16, no. 5 (October 2011): 405–11. http://dx.doi.org/10.1016/j.cocis.2011.06.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Maurya, Priyanka, Saman Fatma, Jai Narayan Mishra, and Ashutosh Kushwaha. "PHARMACEUTICAL PRONIOSOMAL DRUG DELIVERY: A COMPLETE REVIEW OF NEW DELIVERY SYSTEM." IJRDO-Journal of Applied Science 8, no. 11 (November 19, 2022): 1–8. http://dx.doi.org/10.53555/as.v8i11.5423.

Full text

Abstract:

Numerous issues arise in the field of solubility augmentation. Pharmacosomes, a revolutionary method based on lipid medication delivery, have emerged. Pharmacosomes are covalently bound, colloidal, nanometric-size micelles, vesicles, or hexagonal assemblies of colloidal drug dispersions to the phospholipid. Due to their special qualities such tiny size, amphiphilicity, active drug loading, high entrapment efficiency, and stability, they serve as suitable carriers for drug administration fairly accurately. In addition to lowering therapy costs, drug leakage and toxicity, increasing the bioavailability of poorly soluble medications, and having restorative benefits, they aid in the regulated release of pharmaceuticals at the site of action. This medication delivery system's capabilities have expanded to accommodate more medicines.

APA, Harvard, Vancouver, ISO, and other styles

35

Filipczak, Nina, Satya Siva Kishan Yalamarty, Xiang Li, Muhammad Muzamil Khan, Farzana Parveen, and Vladimir Torchilin. "Lipid-Based Drug Delivery Systems in Regenerative Medicine." Materials 14, no. 18 (September 17, 2021): 5371. http://dx.doi.org/10.3390/ma14185371.

Full text

Abstract:

The most important goal of regenerative medicine is to repair, restore, and regenerate tissues and organs that have been damaged as a result of an injury, congenital defect or disease, as well as reversing the aging process of the body by utilizing its natural healing potential. Regenerative medicine utilizes products of cell therapy, as well as biomedical or tissue engineering, and is a huge field for development. In regenerative medicine, stem cells and growth factor are mainly used; thus, innovative drug delivery technologies are being studied for improved delivery. Drug delivery systems offer the protection of therapeutic proteins and peptides against proteolytic degradation where controlled delivery is achievable. Similarly, the delivery systems in combination with stem cells offer improvement of cell survival, differentiation, and engraftment. The present review summarizes the significance of biomaterials in tissue engineering and the importance of colloidal drug delivery systems in providing cells with a local environment that enables them to proliferate and differentiate efficiently, resulting in successful tissue regeneration.

APA, Harvard, Vancouver, ISO, and other styles

36

Matta, Vasu Deva Reddy. "A concise review on preparation methods used for the development of solid lipid nanoparticles." Journal of Drug Delivery and Therapeutics 11, no. 1-s (February 15, 2021): 162–69. http://dx.doi.org/10.22270/jddt.v11i1-s.4687.

Full text

Abstract:

Solid lipid nanoparticles (SLNs) are in submicron size range nanoparticles and are made of biocompatible and biodegradable materials (mainly composed of lipids and surfactants) capable of incorporating both lipophilic and hydrophilic drugs. SLNs are also considered as substitute to other colloidal drug systems, also used as controlled systems and targeted delivery. SLNs can be considered as an alternative for oral drug delivery vehicle to improve the oral bioavailability of drugs, associated reduction of drug toxicity and stability of drug in both GIT and plasma. There are different techniques used for the preparation of SLNs. Generally, the preparation of SLNs and any other nanoparticle system necessitates a dispersed system as precursor; otherwise particles are produced through the use of a particular instrumentation. This review provides the summary on the techniques or methods used for the development of SLNs of poorly water soluble drugs for improved drug delivery. Keywords: Solid lipid nanoparticles, controlled delivery, precursor, techniques.

APA, Harvard, Vancouver, ISO, and other styles

37

Rajalakshmi, G., C. K. Dhanapal, and R. Sundhararajan. "An Insight to Nanostructured Lipid Carrier System." Journal of Drug Delivery and Therapeutics 10, no. 6-s (December 15, 2020): 173–82. http://dx.doi.org/10.22270/jddt.v10i6-s.4589.

Full text

Abstract:

In pharmaceutical field, many drugs are being invented to combat the existing new diseases. The winds of change in the drug scenario are blowing forcefully worldwide. The emergence of new technologies provides an unique opportunities to exploit novel approaches in drug delivery. A shift from conventional drug delivery to novel drug delivery is noticed as shift from conventional drug delivery suffers from various drawbacks, But these new mighty compounds in drug therapy solely are not sufficient to meet the today’s need. There is an urgent need for the smart technology, as the drugs available suffer from serious problems like poor solubility and poor bioavailability. Most of the drugs that are available therapeutically comes under BCS class II ie, poorly soluble and high lipophilc. To assure progress in drug therapy, the development of new drugs merely is not sufficient. Issues arising in delivery of new drugs should also be addressed. Thus there is an emergent need to improve the bioavailability of these drugs, the only remedy or boon for such drugs is the discovery of some smart technologies which can improve the bioavailability of these drugs. Nano drug delivery systems are the one such universal approach which fulfills the lacuna, which exists in conventional drug delivery systems. These Nano drug delivery systems, improves the pharmacokinetic profiles of many drugs. In 1980 K. Eric Drexler developed and popularized the concept of nanotechnology. In this review a deep insight on Nano structured lipid carriers is discussed elaborating its birth, significant qualities compared to other colloidal systems, its structure, characteristics, preparation and application are spotted. Key words: BCS class, Lipophilic, Nano technology, Nano structured lipid carrier.

APA, Harvard, Vancouver, ISO, and other styles

38

Thirupathi, Gorre, Samanthula Kumara Swamy, and Alli Ramesh. "Solid lipid nanocarriers as alternative drug delivery system for improved oral delivery of drugs." Journal of Drug Delivery and Therapeutics 10, no. 6-s (December 15, 2020): 168–72. http://dx.doi.org/10.22270/jddt.v10i6-s.4410.

Full text

Abstract:

Oral bioavailability of drugs is mainly limited due to the poor aqueous solubility, enhanced chemical degradation, reduced permeation and/or first pass metabolism. Various novel delivery systems are developed for improved oral bioavailability of these drugs such as modified orals, buccal, transdermal and osmotic delivery systems. Colloidal carrier systems such as nanoparticles, lipid nanoparticles, nanoemulsions, microspheres, liposomes, resealed erythrocytes and transfersomes were also developed to enhance the oral delivery. Among these, solid lipid nanocarriers (SLNs) also gain much attention on the enhancement of oral bioavailability. SLNs are submicron sized nanoparticles and composed of solid lipid, surfactants and cosurfactants. The enhanced oral bioavailability of poorly soluble drugs from SLNs might be due to the reduced particle size, bypassed presystemic metabolism, and enhanced gastric mucosa permeability. Vast literature is available for the advantages, limitations, preparation methods, evaluation parameters and application of SLNs in different routes. This review mainly focused on list of drugs developed as SLNs and considered as an alternative approach to enhance the oral bioavailability based on pharmacokinetic as well as pharmacodyanmic parameters was discussed. Keywords: Oral bioavailability, solubility, first-pass metabolism, solid lipid nanoparticles, pharmacokinetics, pharmacodynamics.

APA, Harvard, Vancouver, ISO, and other styles

39

Mansor, Nur Izzati, Norshariza Nordin, Farahidah Mohamed, King Hwa Ling, Rozita Rosli, and Zurina Hassan. "Crossing the Blood-Brain Barrier: A Review on Drug Delivery Strategies for Treatment of the Central Nervous System Diseases." Current Drug Delivery 16, no. 8 (October 9, 2019): 698–711. http://dx.doi.org/10.2174/1567201816666190828153017.

Full text

Abstract:

: Many drugs have been designed to treat diseases of the central nervous system (CNS), especially neurodegenerative diseases. However, the presence of tight junctions at the blood-brain barrier has often compromised the efficiency of drug delivery to target sites in the brain. The principles of drug delivery systems across the blood-brain barrier are dependent on substrate-specific (i.e. protein transport and transcytosis) and non-specific (i.e. transcellular and paracellular) transport pathways, which are crucial factors in attempts to design efficient drug delivery strategies. This review describes how the blood-brain barrier presents the main challenge in delivering drugs to treat brain diseases and discusses the advantages and disadvantages of ongoing neurotherapeutic delivery strategies in overcoming this limitation. In addition, we discuss the application of colloidal carrier systems, particularly nanoparticles, as potential tools for therapy for the CNS diseases.

APA, Harvard, Vancouver, ISO, and other styles

40

Zielińska, Aleksandra, Amanda Cano, Tatiana Andreani, Carlos Martins-Gomes, Amélia M. Silva, Marlena Szalata, Ryszard Słomski, and Eliana B. Souto. "Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol." International Journal of Molecular Sciences 23, no. 11 (May 31, 2022): 6165. http://dx.doi.org/10.3390/ijms23116165.

Full text

Abstract:

Lipid nanoparticles are currently used to deliver drugs to specific sites in the body, known as targeted therapy. Conjugates of lipids and drugs to produce drug-enriched phospholipid micelles have been proposed to increase the lipophilic character of drugs to overcome biological barriers. However, their applicability at the topical level is still minimal. Phospholipid micelles are amphiphilic colloidal systems of nanometric dimensions, composed of a lipophilic nucleus and a hydrophilic outer surface. They are currently used successfully as pharmaceutical vehicles for poorly water-soluble drugs. These micelles have high in vitro and in vivo stability and high biocompatibility. This review discusses the use of lipid-drug conjugates as biocompatible carriers for cutaneous application. This work provides a metadata analysis of publications concerning the conjugation of cannabidiol with lipids as a suitable approach and as a new delivery system for this drug.

APA, Harvard, Vancouver, ISO, and other styles

41

Merkulova, M. A., N. S. Osipova, A. V. Kalistratova, Yu V. Ermolenko, and S. E. Gel’perina. "Etoposide-Loaded Colloidal Delivery Systems Based on Biodegradable Polymeric Carriers." Коллоидный журнал 85, no. 5 (September 1, 2023): 593–618. http://dx.doi.org/10.31857/s0023291223600463.

Full text

Abstract:

The review is focused on the etoposide delivery systems based on colloidal carriers, i.e., nanoparticles and micelles made of synthetic and natural polymers. Etoposide, a topoisomerase II inhibitor, occupies an important place in the chemotherapy of a number of tumors; however, its use is often limited due to severe side effects. The application of colloidal delivery systems makes it possible to change the pharmacokinetic parameters of etoposide and increase its accumulation in tumors leading to an increase in the antitumor effect. Of particular interest are stimuli-sensitive systems that respond to specific conditions in the tumor microenvironment, which can significantly increase the selectivity of the drug.

APA, Harvard, Vancouver, ISO, and other styles

42

Gigliobianco, Maria, Cristina Casadidio, Roberta Censi, and Piera Di Martino. "Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability." Pharmaceutics 10, no. 3 (August 21, 2018): 134. http://dx.doi.org/10.3390/pharmaceutics10030134.

Full text

Abstract:

Many approaches have been developed over time to overcome the bioavailability limitations of poorly soluble drugs. With the advances in nanotechnology in recent decades, science and industry have been approaching this issue through the formulation of drugs as nanocrystals, which consist of “pure drugs and a minimum of surface active agents required for stabilization”. They are defined as “carrier-free submicron colloidal drug delivery systems with a mean particle size in the nanometer range, typically between 10–800 nm”. The primary importance of these nanoparticles was the reduction of particle size to nanoscale dimensions, with an increase in the particle surface area in contact with the dissolution medium, and thus in bioavailability. This approach has been proven successful, as demonstrated by the number of such drug products on the market. Nonetheless, despite the definition that indicates nanocrystals as a “carrier-free” system, surface active agents are necessary to prevent colloidal particles aggregation and thus improve stability. In addition, in more recent years, nanocrystal properties and technologies have attracted the interest of researchers as a means to obtain colloidal particles with modified biological properties, and thus their interest is now also addressed to modify the drug delivery and targeting. The present work provides an overview of the achievements in improving the bioavailability of poorly soluble drugs according to their administration route, describes the methods developed to overcome physicochemical and stability-related problems, and in particular reviews different stabilizers and surface agents that are able to modify the drug delivery and targeting.

APA, Harvard, Vancouver, ISO, and other styles

43

Okur, Neslihan Ü., Ece Ö. Bülbül, Ayşe P. Yağcılar, and Panoraia I. Siafaka. "Current Status of Mucoadhesive Gel Systems for Buccal Drug Delivery." Current Pharmaceutical Design 27, no. 17 (June 17, 2021): 2015–25. http://dx.doi.org/10.2174/1381612824666210316101528.

Full text

Abstract:

Background: Buccal drug delivery is a fascinating research field. Gel-based formulations present potent characteristics as buccal systems since they have great physicochemical properties. Methods: Among the various gels, in situ gels that are viscous colloidal systems consisted of polymers when physiological conditions change (pH, temperature, ion activation) shift to the gel phase. These systems can improve bioavailability. Other systems such as nanogels or emulgels can be also applied for buccal delivery with promising results. Polymeric gel-based systems can be produced by natural, semisynthetic, and synthetic polymers. Their main advantage is that the active molecules can be released in a sustained and controllable manner. Several gels based on chitosan are produced for the entrapment of drugs demonstrating efficient retention time and bioavailability, due to chitosan mucoadhesion. Besides polysaccharides, poloxamers and Carbopol are also used in buccal gels due to their high swelling ability and reversed thermal gelation behavior. Results: Herein, the authors focused on the current development of mucoadhesive gel systems used in buccal drug delivery. After explaining buccal drug delivery and mucoadhesion, various studies with hydrogels, in situ gels, and nanogels were analyzed as buccal gel systems. Various mucoadhesive gel studies with mucoadhesive polymers have been studied and summarized. This review is presented as valuable guidance to scientists in formulating buccal mucoadhesive drug delivery systems. Conclusions: This review aimed to assist researchers working on buccal drug delivery by summarizing buccal drug delivery, mucoadhesion, and buccal mucoadhesive gel systems recently found in the literature.

APA, Harvard, Vancouver, ISO, and other styles

44

Li, Shuzhen, Wanqiong Li, Xin Yang, Yanfeng Gao, and Guanyu Chen. "Dietary-Polysaccharide-Modified Fish-Oil-Based Double Emulsion as a Functional Colloidal Formulation for Oral Drug Delivery." Pharmaceutics 14, no. 12 (December 19, 2022): 2844. http://dx.doi.org/10.3390/pharmaceutics14122844.

Full text

Abstract:

Oral delivery is the most convenient drug administration route. However, oral delivery of peptides is extremely challenging due to the physical and chemical barriers within the gastrointestinal tract. Polysaccharides are often utilized as polymeric biomaterials in drug delivery. Among these, dietary polysaccharides extracted from okra, yam, and spirulina have been reported to stimulate innate immunity with well-known nutritional benefits. In this study, we developed a dietary-polysaccharide-modified fish-oil-based emulsion for oral co-delivery of a hydrophilic PD-L1 blocking peptide and the hydrophobic small molecule simvastatin. The optimal emulsion was nano-sized and exhibited a negative surface charge, high drug encapsulation efficiency of over 97%, low viscosity, and sustained drug release manner. The formulation could significantly increase the uptake of peptides by intestinal Caco-2 cells, which demonstrated the great potential of the formulation for promoting the oral absorption of peptides. Additionally, these dietary polysaccharides could promote dendritic cell maturation and cytokine expression in macrophages, demonstrating that these nutraceutical polysaccharides had dual roles of functioning as promising colloidal delivery systems and as potential immune modulators or adjuvants. Thus, this food-based colloidal delivery system shows promise for the oral delivery of peptide drugs and lays a great platform for future applications in immunotherapy.

APA, Harvard, Vancouver, ISO, and other styles

45

Dudhipala, Narendar. "A Comprehensive Review on Solid Lipid Nanoparticles as Delivery Vehicle for Enhanced Pharmacokinetic and Pharmacodynamic Activity of Poorly Soluble Drugs." International Journal of Pharmaceutical Sciences and Nanotechnology 12, no. 2 (March 31, 2019): 4421–40. http://dx.doi.org/10.37285/ijpsn.2019.12.2.1.

Full text

Abstract:

This article describes the current state and future perspectives of solid lipid nanoparticles for achieving high delivery of drugs with greater therapeutic outcomes. The oral route is the most preferred route of administration for majority of drugs. Problems such as poor solubility or chemical stability in the environment of the gastrointestinal tract, poor permeability through the biological membranes or sensitivity to metabolism are well known to result in the rejection of potential drug candidates as oral delivery products. Hence, lipid-based drug delivery systems have been proposed as a means of bypassing the resistant chemical or physical barriers associated with poorly absorbed drugs. Solid lipid nanoparticles (SLNs) can be an attractive one option for oral drug delivery vehicles as they hold tremendous potential to improve the oral bioavailability of drugs, concomitant reduction of drug toxicity and stability of drug in both GIT and plasma. SLNs are in submicron size range and are made of biocompatible and biodegradable materials capable of incorporating both lipophilic and hydrophilic drugs. SLNs are considered as substitute to other colloidal drug systems and are being used as controlled and targeted delivery systems. The SNL technology has greatly revolutionized the delivery systems for poorly soluble drugs. This article describes the methodologies used for preparation and characterization of SNLs. It outlined the development of stable solid lipid nanoparticles by different techniques. Further, it describes the current status of pharmacokinetic and pharmaco-dynamic studies reported on SLN systems. Finally, it provides a brief outlook on current marketed preparation and the future scope of SLN technology.

APA, Harvard, Vancouver, ISO, and other styles

46

Pinelli, Filippo, Giuseppe Perale, and Filippo Rossi. "Coating and Functionalization Strategies for Nanogels and Nanoparticles for Selective Drug Delivery." Gels 6, no. 1 (February 4, 2020): 6. http://dx.doi.org/10.3390/gels6010006.

Full text

Abstract:

Drug delivery is a fascinating research field with several development opportunities. Great attention is now focused on colloidal systems, nanoparticles, and nanogels and on the possibility of modifying them in order to obtain precise targeted drug delivery systems. The aim of this review is to give an overview of the main available surface functionalization and coating strategies that can be adopted in order to modify the selectivity of the nanoparticles in the delivery process and obtain a final system with great targeted drug delivery ability. We also highlight the most important fields of application of these kinds of delivery systems and we propose a comparison between the advantages and disadvantages of the described functionalization strategies.

APA, Harvard, Vancouver, ISO, and other styles

47

Ferderber, Kristina, Sarah Hook, and Thomas Rades. "Phosphatidyl choline-based colloidal systems for dermal and transdermal drug delivery." Journal of Liposome Research 19, no. 4 (October 28, 2009): 267–77. http://dx.doi.org/10.3109/08982100902814006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Pippa, Natassa, Costas Demetzos, and Emmanuel Danezis. "The formalism of fractal aggregation phenomena of colloidal drug delivery systems." Journal of Liposome Research 22, no. 1 (July 20, 2011): 55–61. http://dx.doi.org/10.3109/08982104.2011.590142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Swathi, G., N. L. Prasanthi, S. S. Manikiran, and N. Ramarao. "ChemInform Abstract: Solid Lipid Nanoparticles: Colloidal Carrier Systems for Drug Delivery." ChemInform 43, no. 2 (December 15, 2011): no. http://dx.doi.org/10.1002/chin.201202274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Wu, Danjun, Agathe Ensinas, Bernard Verrier, Armelle Cuvillier, Gaël Champier, Stephane Paul, and Thierry Delair. "Ternary polysaccharide complexes: Colloidal drug delivery systems stabilized in physiological media." Carbohydrate Polymers 172 (September 2017): 265–74. http://dx.doi.org/10.1016/j.carbpol.2017.05.051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Colloidal drug delivery systems'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles